The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study

International Journal of Cancer

Volumn 130, Issue 9, 2012, Pages 2118-2128

  Van Hemelrijck, Mieke ^a   Garmo, Hans ^a,b   Hammar, Niklas ^c,d   Jungner, Ingmar ^c   Walldius, Göran ^c   Lambe, Mats ^b,c   Holmberg, Lars ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

apolipoprotein A I; apolipoprotein B; glucose; HDL cholesterol; kidney cancer; LDL cholesterol; total cholesterol; triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CANCER MORTALITY; CANCER RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY CANCER; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SWEDEN; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; GLUCOSE; HUMANS; KIDNEY NEOPLASMS; LIPID METABOLISM; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TRIGLYCERIDES;

EID: 84857504888     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26212     Document Type: Article

References (32)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D,. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer, 2010.
2. Drabkin HA, Gemmill RM,. Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC). Adv Cancer Res 2010; 107: 39-56.
3. Rutkowski P, Klassen A, Sebekova K, Bahner U, Heidland A,. Renal disease in obesity: the need for greater attention. J Ren Nutr 2006; 16: 216-23.
4. Chow WH, Devesa SS,. Contemporary epidemiology of renal cell cancer. Cancer J 2008; 14: 288-301.
5. Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC,. Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes Control 2002; 13: 287-93.
6. Brock KE, Gridley G, Chiu BC, Ershow AG, Lynch CF, Cantor KP,. Dietary fat and risk of renal cell carcinoma in the USA: a case-control study. Br J Nutr 2009; 101: 1228-38.
7. Dombrowski F, Klotz L, Bannasch P, Evert M,. Renal carcinogenesis in models of diabetes in rats: metabolic changes are closely related to neoplastic development. Diabetologia 2007; 50: 2580-90.
8. Galeone C, Pelucchi C, Maso LD, Negri E, Talamini R, Montella M, Ramazzotti V, Bellocco R, Franceschi S, La Vecchia C,. Glycemic index, glycemic load and renal cell carcinoma risk. Ann Oncol 2009; 20: 1881-5.
9. Washio M, Mori M, Khan M, Sakauchi F, Watanabe Y, Ozasa K, Hayashi K, Miki T, Nakao M, Mikami K, Ito Y, Kubo T, et al. Diabetes mellitus and kidney cancer risk: the results of Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study). Int J Urol 2007; 14: 393-7.
10. Zucchetto A, Dal Maso L, Tavani A, Montella M, Ramazzotti V, Talamini R, Canzonieri V, Garbeglio A, Negri E, Franceschi S, La Vecchia C,. History of treated hypertension and diabetes mellitus and risk of renal cell cancer. Ann Oncol 2007; 18: 596-600.
11. Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E,. Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 1998; 44 (8, Part 1): 1641-9.
12. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E,. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
13. Holme I, Aastveit AH, Jungner I, Walldius G,. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2008; 264: 30-8.
14. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G,. Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009; 265: 275-87.
15. Walldius G, Jungner I, Kolar W, Holme I, Steiner E,. High cholesterol and triglyceride values in Swedish males and females: increased risk of fatal myocardial infarction. First report from the AMORIS (Apolipoprotein related MOrtality RISk) study. Blood Press Suppl 1992; 4: 35-42.
16. Van Hemelrijck M, Garmo H, Binda E, et al. Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes and Control 2010: 21: 1657-67.
17. Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N, Lambe M,. Prostate cancer risk in the Swedish AMORIS study: The interplay among triglycerides, total cholesterol, and glucose. Cancer 2011: 17: 2086-95.
18. Central Bureau for Statistics. Statistics Sweden. Stockholm, Sweden: Central Bureau for Statistics, 2008.
19. Jungner I, Walldius G, Holme I, Kolar W, Steiner E,. Apolipoprotein B and A-I in relation to serum cholesterol and triglycerides in 43,000 Swedish males and females. Int J Clin Lab Res 1992; 21: 247-55.
20. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Newman AB, Siscovick DS, Stevens L, Sarnak MJ,. Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C. Am J Nephrol 2009; 30: 171-8.
21. Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF, Massana L, Mangas A, Hernandez Mijares A, Gonzalez-Santos P, Ascaso JF, Pedro-Botet J,. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 2009; 5: 757-65.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 2001; 285: 2486-97.
23. Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, Virtamo J, Albanes D,. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2814-21.
24. Gebhard RL, Clayman RV, Prigge WF, Figenshau R, Staley NA, Reesey C, Bear A,. Abnormal cholesterol metabolism in renal clear cell carcinoma. J Lipid Res 1987; 28: 1177-84.
25. Lontie JF, Dubois DY, Carpentier YA,. Abnormal lipoprotein and marked hypercholesterolemia as paraneoplastic manifestation of a renal adenocarcinoma. Atherosclerosis 2001; 155: 261-2.
26. Bidoli E, Talamini R, Zucchetto A, Polesel J, Bosetti C, Negri E, Maruzzi D, Montella M, Franceschi S, La Vecchia C,. Macronutrients, fatty acids, cholesterol and renal cell cancer risk. Int J Cancer 2008; 122: 2586-9.
27. Lee JE, Spiegelman D, Hunter DJ, Albanes D, Bernstein L, van den Brandt PA, Buring JE, Cho E, English DR, Freudenheim JL, Giles GG, Graham S, et al. Fat, protein, and meat consumption and renal cell cancer risk: a pooled analysis of 13 prospective studies. J Natl Cancer Inst 2008; 100: 1695-706.
28. Babayan RK, Devereux DF,. Alteration of lipid metabolism associated with renal adenocarcinoma in the Wistar-Lewis rat. J Urol 1984; 132: 410-1.
29. Talley DJ, Sadowski JA, Boler SA, Li JJ,. Changes in lipid profiles of estrogen-induced and transplanted renal carcinomas in Syrian hamsters. Int J Cancer 1983; 32: 617-21.
30. Borena W, Stocks T, Jonsson H, Strohmaier S, Nagel G, Bjorge T, Manjer J, Hallmans G, Selmer R, Almquist M, Haggstrom C, Engeland A, et al. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 2011; 22: 291-9.
31. Ulmer H, Borena W, Rapp K, Klenk J, Strasak A, Diem G, Concin H, Nagel G,. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer 2009; 101: 1202-6.
32. Van Hemelrijck M, Jungner I, Walldius G, Garmo H, Binda E, Hayday A, Lambe M, Holmberg L, Hammar N,. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int J Cancer (2010): Published online Nov 15.